These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12485972)

  • 21. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of intravenous infusion and oral self-administration of cocaine on plasma and adrenal catecholamine levels and cardiovascular parameters in the conscious rat.
    Dixon WR; Chang AP; Machado J; Lau B; Thompson A; Gallagher S; Sanders W
    NIDA Res Monogr; 1989; 95():335-6. PubMed ID: 2640986
    [No Abstract]   [Full Text] [Related]  

  • 23. [The effect of the activation of the sympathetic-adrenal system on the pulmonary inactivation of catecholamines in rats].
    Bonetskiĭ AA; Fedorov VI
    Fiziol Zh SSSR Im I M Sechenova; 1992 Feb; 78(2):81-6. PubMed ID: 1330737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy.
    Nemanich JW; Veith RC; Abrass IB; Stratton JR
    Am J Cardiol; 1990 Oct; 66(10):843-8. PubMed ID: 2220583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment.
    Nigmatullina RR; Kirillova VV; Jourjikiya RK; Mukhamedyarov MA; Kudrin VS; Klodt PM; Palotás A
    Cardiology; 2009; 113(4):277-86. PubMed ID: 19270454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sympathetic inhibition with clonidine prolongs survival in experimental chronic heart failure.
    Zhang Y; Cheng Z
    Int J Cardiol; 2000 Apr; 73(2):157-62; discussion 163-4. PubMed ID: 10817854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The autonomic nervous system in congestive heart failure.
    Francis GS; Cohn JN
    Annu Rev Med; 1986; 37():235-47. PubMed ID: 2871803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of acute and chronic vasodilator administration on hemodynamics and catecholamine concentration in chronic left heart failure (author's transl)].
    Klein W; Goebel R
    Z Kardiol; 1980 Feb; 69(2):120-5. PubMed ID: 6779433
    [No Abstract]   [Full Text] [Related]  

  • 30. Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure.
    Palkhiwala SA; Yu A; Frishman WH
    Heart Dis; 2000; 2(1):83-92. PubMed ID: 11728244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship among neuropeptide Y, catecholamines and haemodynamics in congestive heart failure.
    Dubois-Randé JL; Comoy E; Merlet P; Benvenuti C; Carville C; Hittinger L; Macquin-Mavier I; Bohuon C; Castaigne A
    Eur Heart J; 1992 Sep; 13(9):1233-8. PubMed ID: 1396834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Central nervous system as a target for the new antihypertensive agents].
    Nurminen ML
    Duodecim; 1999; 115(20):2267-73. PubMed ID: 11973931
    [No Abstract]   [Full Text] [Related]  

  • 33. Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients.
    Lambert GW; Kaye DM; Lefkovits J; Jennings GL; Turner AG; Cox HS; Esler MD
    Circulation; 1995 Oct; 92(7):1813-8. PubMed ID: 7545554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of barbiturate anaesthesia on stress activation of the sympathico-adrenal system; an attempt to determine stress-induced stimulation of liver glycogen phosphorylase in spite of this effect.
    Németh S; Viskupic E; Kvetnanský R; Jindra A
    Physiol Bohemoslov; 1983; 32(3):247-54. PubMed ID: 6611709
    [No Abstract]   [Full Text] [Related]  

  • 35. Regulation of catecholamine secretion by endogenous opioid peptides.
    Van Loon GR; Appel NM; Ho D
    Prog Clin Biol Res; 1981; 74():293-318. PubMed ID: 6275405
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of the centrally acting agent clonidine on circulating catecholamines at rest and during exercise. Comparison with the effects of beta-blocking agents.
    Mäurer W; Hausen M; Krämer B; Kübler W
    Chest; 1983 Feb; 83(2 Suppl):366-9. PubMed ID: 6129951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma catecholamines, cyclic AMP and metabolic substrates in hemorrhagic shock of the rat. The effect of adrenal demedullation and 6-OH-dopamine treatment.
    Fredholm BB; Farnebo LO; Hamberger B
    Acta Physiol Scand; 1979 Apr; 105(4):481-95. PubMed ID: 222118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of clonidine on renal sympathetic nerve activity, natriuresis and diuresis in chronic congestive heart failure rats.
    Feng QP; Carlsson S; Thorén P; Hedner T
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1129-35. PubMed ID: 1534840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Blood levels of activated renin, aldosterone, catecholamine in congestive heart failure. I. Role of the adrenergic and dopaminergic systems].
    Melloni R; Scarazatti E; Gandini C; Melloni GF
    Boll Soc Ital Biol Sper; 1987 Dec; 63(12):1113-20. PubMed ID: 3331289
    [No Abstract]   [Full Text] [Related]  

  • 40. Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure.
    Majid PA; Morris WM; Sole MJ
    Can J Cardiol; 1987 Mar; 3(2):70-4. PubMed ID: 3567710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.